Abstract
Objectives To explore clustering of comorbidities among patients with a new diagnosis of osteoarthritis (OA) and estimate the 10-year mortality risk for each identified cluster.
Methods This is a population-based cohort study of individuals with first incident diagnosis of OA of the hip, knee, ankle/foot, wrist/hand, or ‘unspecified’ site between 2006 and 2020, using SIDIAP (a primary care database representative from Catalonia, Spain). At the time of OA diagnosis, conditions associated with OA in the literature that were found in ≥1% of the individuals (n=35) were fitted into two cluster algorithms, K-means and latent class analysis (LCA). Models were assessed using a range of internal and external evaluation procedures. Mortality risk of the obtained clusters was assessed by survival analysis using Cox proportional hazards.
Results We identified 633,330 patients with a diagnosis of OA. Our proposed best solution used LCA to identify four clusters: ‘Low-morbidity (relatively low number of comorbidities), ‘Back/neck pain plus mental health’, ‘Metabolic syndrome’ and ‘Multimorbidity’ (higher prevalence of all study comorbidities). Compared to the ‘Low-morbidity, the ‘Multimorbidity’ cluster had the highest risk of 10-year mortality (adjusted HR: 2.19 [95%CI: 2.15-2.23]), followed by ‘Metabolic syndrome’ (adjusted HR: 1.24 [95%CI: 1.22-1.27]]) and ‘Back/neck pain plus mental health’ (adjusted HR: 1.12 [95%CI: 1.09-1.15]).
Conclusion Patients with a new diagnosis of OA can be clustered into groups based on their comorbidity profile, with significant differences in 10-year mortality risk. Further research is required to understand the interplay between OA and particular comorbidity groups, and the clinical significance of such results.
Key Messages
Patients with newly diagnosed osteoarthritis can by classified into different clusters by their comorbidity patterns.
Such classification can help identify ‘high-risk’ patients who require more intense attention from healthcare providers.
The main patient sub-groups were ‘Low-morbidity’, ‘Back/neck pain plus mental health’, ‘Metabolic syndrome’ and ‘Multimorbidity’.
Competing Interest Statement
DPA receives funding from the UK National Institute for Health and Care Research (NIHR) in the form of a senior research fellowship and from the Oxford NIHR Biomedical Research Centre. His research group has received funding form the European Medicines Agency and Innovative Medicines Initiative. His research group has received research grant/s from Amgen, Chiesi-Taylor, GSK, Novartis, and UCB Biopharma. His department has also received advisory or consultancy fees from Amgen, Astellas, Astra Zeneca, Johnson and Johnson, and UCB Biopharma; and speaker fees from Amgen and UCB Biopharma. Janssen and Synapse Management Partners have supported training programmes organised by DPAs department and open for external participants organized by his department outside the submitted work. AKs Institute received/receives FOREUM grant for the contributions of the (co)authors of this institution to the entire project. JR and SS research group receives FOREUM research grant. WZ received European Foundation of Research for Rheumatology (FOREUM grant to support the project, NIHR-BRC Centre for infrastructure support and Pain Centre Versus Arthritis centre grant for infrastructure support and also received consulting fees from Eli Lily and Regeneration in the form of advisory board, speakers fees from Harbin Rheumatology, and Shenzhen Rheumatology and Infection Summit and also received payment/ honoraria for lectures, presentation, manuscript writing/ educational events. VS is a Full-time employee in Boehringer-Ingelheim since Feb 2022 and receives payment from Pfizer for lectures. SK receives grant from Health Data Research UK, the Alan Turing Institute and Amgen BioPharma. AD, IP, DR, MPM, FD and ME has nothing to declare.
Funding Statement
This research was founded by the Foundation for Research in Rheumatology (FOREUM) grant (2019-2022).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Scientific Committee SIDIAP and the Clinical Research Ethics Committee of the IDIAP Jordi Gol gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first authors,
Data Availability
Data that supports the findings of this study was provided by SIDIAP database. Data access is limited to researchers from public institutions, and collaboration with private organizations is only allowed for studies required by a regulatory agency or for non-commercial studies within a European project financed by the European Commission. Moreover, availability of data is subject to protocol approval by SIDIAPs Scientific Committee and Clinical Research Ethics Committee of IDIAPJGol.
